BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

• Anastasia Wyce,

  Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Gopinath Ganji,

  Affiliation Molecular Medicine Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Kimberly N. Smitheman,

  Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Chun-wa Chung,

  Affiliation Platform Technology and Science, GlaxoSmithKline, Stevenage, United Kingdom

  ⨯
• Susan Korenchuk,

  Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Yuchen Bai,

  Affiliation Molecular Medicine Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Olena Barbash,

  Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• BaoChau Le,

  Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Peter D. Craggs,

  Affiliation Platform Technology and Science, GlaxoSmithKline, Stevenage, United Kingdom

  ⨯
• Michael T. McCabe,

  Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Karen M. Kennedy-Wilson,

  Affiliation Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Lydia V. Sanchez,

  Affiliation Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Romain L. Gosmini,

  Affiliation Lipid Metabolism Discovery Performance Unit, GlaxoSmithKline, Les Ulis, France

  ⨯
• Nigel Parr,

  Affiliation Epinova Discovery Performance Unit, GlaxoSmithKline, Stevenage, United Kingdom

  ⨯
• Charles F. McHugh,

  Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Dashyant Dhanak,

  Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Rab K. Prinjha,

  Affiliation Epinova Discovery Performance Unit, GlaxoSmithKline, Stevenage, United Kingdom

  ⨯
• Kurt R. Auger,

  Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
•  [ ... ],
• Peter J. Tummino

  * E-mail: Peter.J.Tummino@gsk.com

  Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• [ view all ]
• [ view less ]